https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 09:13:302024-03-14 09:13:30Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:56:272024-03-14 09:14:41Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:09:382024-03-14 08:09:38Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
https://www.optimumcomms.com/wp-content/uploads/2024/03/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:07:482024-03-14 12:04:02Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-13 08:57:002024-03-13 08:57:00Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-12 08:40:452024-03-12 08:40:45Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ionctura_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-07 08:10:082024-03-07 08:10:08US FDA grants Orphan Drug Designation for iOnctura’s first-in-class autotaxin cancer therapy
https://www.optimumcomms.com/wp-content/uploads/2023/08/Bioinnovation_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-07 08:06:382024-03-07 08:06:38BioInnovation Institute provides financial support as six promising companies enter the Venture House program
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 11:05:252024-03-06 11:05:25Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 09:19:262024-03-08 09:21:12Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
https://www.optimumcomms.com/wp-content/uploads/2023/09/WiLD_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:44:442024-03-06 14:41:55Women in Life Science Denmark (WiLD) to host network meeting in collaboration with DANISH BIO to promote equity in the Danish life science industry
https://www.optimumcomms.com/wp-content/uploads/2023/02/ASCEneuron_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:41:032024-03-06 08:41:03Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:35:482024-03-06 08:35:48Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 16:19:392024-03-05 16:19:39Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients
https://www.optimumcomms.com/wp-content/uploads/2024/03/LinkedIn-Logo.jpg
200
200
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 11:02:472024-03-05 11:02:47Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 08:39:412024-03-05 08:39:41Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 08:38:282024-03-05 08:38:28Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-04 12:00:572024-03-05 12:36:15Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-01 09:20:032024-03-01 09:20:034SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-29 08:47:152024-02-29 08:47:15Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent GlioblastomaFor more information about Optimum Strategic Communications, please get in touch.
